CASI Pharmaceuticals Inc (NASDAQ:CASI) Director Wei-Wu He bought 1,871,605 shares of the company’s stock in a transaction that occurred on Monday, October 3rd. The shares were acquired at an average price of $1.19 per share, for a total transaction of $2,227,209.95. Following the completion of the purchase, the director now owns 24,698 shares in the company, valued at $29,390.62. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

CASI Pharmaceuticals Inc (NASDAQ:CASI) opened at 1.22 on Friday. The stock’s market capitalization is $60.34 million. CASI Pharmaceuticals Inc has a 52 week low of $0.58 and a 52 week high of $1.82. The company’s 50-day moving average price is $1.12 and its 200 day moving average price is $1.18.

CASI Pharmaceuticals (NASDAQ:CASI) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.04. Equities research analysts expect that CASI Pharmaceuticals Inc will post ($0.28) EPS for the current fiscal year.

Separately, Maxim Group started coverage on CASI Pharmaceuticals in a research note on Wednesday, September 21st. They set a “buy” rating and a $4.00 target price on the stock.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

5 Day Chart for NASDAQ:CASI

Receive News & Stock Ratings for CASI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.